Industry Partner Members

Corcept Therapeutics

Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In oncology, activation of the glucocorticoid receptor by cortisol may suppress apoptotic pathways, thereby reducing chemotherapy efficacy. Corcept is committed to investigating the role of selective GR antagonists (SGRAs) with clinical studies in ovarian, endometrial, cervical, pancreatic and prostate cancer. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com.

GSK

GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

Pfizer

Our Purpose: We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.

Genmab

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn.

Merck

Who We Are

We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.

Verastem Oncology

Beyond their initial diagnosis, one of the worst things a patient with cancer can hear is that they have run out of options. At Verastem Oncology, we’re on a mission to make sure no patient ever has to hear that news. We embrace the power of partnership and collaboration to develop novel cancer therapies. It’s through these collaborations that we’ll bring hope to patients with RAS pathway-driven cancers. Purposeful. Unwavering. Influential. Insightful. Symbiotic. This is what drives us forward. Together, we look to see where an unexplored pathway will lead us.

BeOne Medicines

BeOne Medicines Purpose
We’re building the world’s leading oncology company – driven by scientific excellence and exceptional speed – to reach more patients than ever before.
Together, we are how the world stops cancer.

Biopharmaceutical New Technologies

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

Genentech

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Genentech manufactures and commercializes several major oncology drugs include Herceptin, Rituxan, Avastin and Tarceva.

PMVPharma

At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Regeneron

Our mission is to use the power of science to bring new medicines to patients … over and over again.

We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

Zentalis

Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.

AbbVie

We are AbbVie

A team of people creating medicines and solutions that put impact first: for patients, communities and our world.

At AbbVie, our people are dedicated to putting patients at the center of everything we do. Every breakthrough, every innovation, and every step forward is inspired by the real lives we touch—working together to improve health and bring hope to individuals and families around the world. Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time.

AstraZeneca

Our Company

Unlocking the power of what science cando for people, society and the planet.

We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders.

Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other disease with high unmet medical need.

Eisai, Inc.

Eisai Inc. is a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).

Gilead | Kite Oncology

Gilead and Kite Oncology are creating the future of oncology. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies and unexpected clinical combinations. We have purposefully built our pipeline with a focus on depth and breadth to address the greatest unmet needs. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers. We are focused on helping to bring more life to people with cancer and changing the way cancer is treated.